New FDA draft guidance details how the agency will determine whether sponsors had “good cause” to not meet required postmarketing study and clinical trial deadlines. Under Section 505(o)(3)(E)(ii) of the Federal Food, Drug, and Cosmetic Act, the FDA can require postmarketing studies and clinical trials for prescription drugs at the time of approval or after approval if the ag... Read More